Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10511464 | 0.84 | EBP (0.56) | SIGMAR1KDM4EMAPK1LMNA | |
| SCHEMBL2923132 | 0.84 | SIGMAR1 (0.58) | SIGMAR1KMT2AKDM4EMEN1TP53 | |
| SCHEMBL17294949 | 0.83 | SIGMAR1 (0.56) | SIGMAR1KMT2AKDM4EMEN1TP53 | |
| SCHEMBL17304776 | 0.83 | SIGMAR1 (0.56) | SIGMAR1KMT2AKDM4EMEN1TP53 | |
| Hydrochloric Acid SCHEMBL3104704 | 0.83 | SIGMAR1 (0.56) | SIGMAR1KMT2AKDM4EMEN1TP53 | |
| SCHEMBL1600111 | 0.81 | KMT2A (0.65) | SIGMAR1KMT2AKDM4EMEN1TP53 | |
| SCHEMBL11460189 | 0.80 | SIGMAR1 (0.50) | SIGMAR1KMT2AKDM4EMEN1TP53 | |
| Phosphoric Acid SCHEMBL3109027 | 0.80 | SIGMAR1 (0.50) | SIGMAR1KMT2AKDM4EMEN1TP53 | |
| Sulfuric Acid SCHEMBL3101978 | 0.80 | SIGMAR1 (0.50) | SIGMAR1KMT2AKDM4EMEN1TP53 | |
| SCHEMBL2917808 | 0.79 | SIGMAR1 (0.52) | SIGMAR1KMT2AKDM4EMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100274003-A1 | ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME | Kukje Pharm Ind co. Ltd (KR) | 2010-10-28 | — | — | US | disclosed |
| EP-1784407-B1 | 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF | KOREA RES INST CHEM TECH (KR) | 2010-09-08 | — | — | EP | disclosed |
| EP-2188287-A2 | ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME | Kukje Pharm. Ind. Co., Ltd. (KR) | 2010-05-26 | — | — | EP | disclosed |
| US-7662810-B2 | Potassium(1R,5S,6S)-2-(1-benzyl-azetidine-3-yl-thio)-6-[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylate; antibacterial activities against Grampositive and Gramnegative bacteria and excellent antibacterial activities against resistant bacteria such as methicillin resistant Staphylococcus aureus | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-02-16 | — | — | US | disclosed |
| WO-2009038328-A2 | ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME | KUKJE PHARM. IND. CO., LTD. (KR) | 2009-03-26 | — | — | WO | disclosed |
| EP-1784407-A4 | 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF | KOREA RES INST CHEM TECH (KR) | 2009-02-11 | — | — | EP | disclosed |
| US-20070244089-A1 | 2- Arylmethylazetidine Carbapenem Derivatives and Preparation Thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2007-10-18 | — | — | US | disclosed |
| EP-1784407-A1 | 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF | Korea Research Institute of Chemical Technology (KR) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006025634-A1 | 2-ARYLMETHYLAZETIDINE CARBAPENEM DERIVATIVES AND PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274003-A1 | ACID ADDITION SALTS OF SYNTHETIC INTERMEDIATES FOR CARBAPENEM ANTIBIOTICS AND PROCESSES FOR PREPARING THE SAME | SLC7A5, SI, ADSL | SIGMAR1 3931/4885KMT2A 1070/4885KDM4E 871/4885 |
| US-20070244089-A1 | 2- Arylmethylazetidine Carbapenem Derivatives and Preparation Thereof | SCN9A, SCN2A, SCN5A | SIGMAR1 2493/4885KMT2A 343/4885KDM4E 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.